Clinical Trial

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-05; most recent amendment 2026-02-04.
Status change: Not Yet Recruiting → Recruiting 2025-09-16
Trial Details
NCT Number NCT06967480
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions Generalized Myasthenia Gravis, Anti-AChR Antibody Positive
Enrollment 40 participants
Start Date 2025-07-31
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-05